A Retrospective Analysis of the Efficacy and Safety of Orelabrutinib-Containing Regimens in Marginal Zone Lymphoma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-198795
Abstract: Background and Objective: Marginal zone lymphoma (MZL) is a prevalent indolent B-cell non-Hodgkin lymphoma (NHL) that remains incurable with standard therapy. The associated treatment toxicity further constrains therapeutic options. Orelabrutinib, a novel BTK inhibitor, is… read more here.
Keywords: treatment; rate; orelabrutinib containing; efficacy ... See more keywords